W Woloszczuk
Overview
Explore the profile of W Woloszczuk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
157
Citations
916
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Piemonte S, Romagnoli E, Bratengeier C, Woloszczuk W, Tancredi A, Pepe J, et al.
J Endocrinol Invest
. 2012 Jul;
35(9):866-8.
PMID: 22842667
Objective: This study was carried out in order to evaluate the effect of 18-month treatment with PTH (1-34) or PTH (1-84) on serum sclerostin levels in humans. Subjects And Methods:...
2.
Polyzos S, Anastasilakis A, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E
Osteoporos Int
. 2011 Feb;
23(3):1171-6.
PMID: 21305266
Unlabelled: Sclerostin is expressed by osteocytes and inhibits bone formation by osteoblasts. In this study, serum sclerostin was positively correlated with either lumbar spinal bone mineral density or T-score. Furthermore,...
3.
Kerschan-Schindl K, Wendlova J, Kudlacek S, Gleiss A, Woloszczuk W, Pietschmann P
Exp Clin Endocrinol Diabetes
. 2007 Dec;
116(8):491-5.
PMID: 18072013
Background: Osteoporosis is one of the most common conditions associated with aging. It is based on an excess of bone resorption over bone formation, leading to an imbalance of bone...
4.
Mikosch P, Igerc I, Kudlacek S, Woloszczuk W, Gallowitsch H, Kresnik E, et al.
Eur J Clin Invest
. 2006 Aug;
36(8):566-73.
PMID: 16893379
Background: Suppressive thyroid hormone therapy is generally a lifelong treatment for patients with differentiated thyroid cancer (DTC). However, long-standing thyrotropin (TSH) suppression is a risk factor for osteoporosis. Osteoprotegerin (OPG)...
5.
Kerschan-Schindl K, Hawa G, Kudlacek S, Woloszczuk W, Pietschmann P
Exp Gerontol
. 2005 Jun;
40(6):532-5.
PMID: 15935595
Bone turnover increases with age. In a previous study, we reported on bone metabolism in young and elderly women and men. The aim of the present investigation was to evaluate...
6.
Skoumal M, Kolarz G, Haberhauer G, Woloszczuk W, Hawa G, Klingler A
Rheumatol Int
. 2005 May;
26(1):63-9.
PMID: 15889303
We examined OPG and soluble RANKL in the serum (sOPG, sRANKL) and synovial fluid (synOPG, synRANKL) in patients with rheumatoid arthritis (RA) and osteoarthritis (OA). OPG and RANKL were measured...
7.
Skoumal M, Kolarz G, Woloszczuk W, Hawa G, Klingler A
Ann Rheum Dis
. 2004 Jan;
63(2):216-7.
PMID: 14722219
No abstract available.
8.
Bobacz K, Maier R, Fialka C, Ekhart H, Woloszczuk W, GEYER G, et al.
Osteoarthritis Cartilage
. 2003 Sep;
11(9):665-72.
PMID: 12954237
Objective: Since the development of posttraumatic osteoarthritis (OA) is a relatively slow process, estimation of OA risk would be of value with regard to chondroprotective measures and medication. In this...
9.
Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R
Bone
. 2003 Jun;
32(6):681-6.
PMID: 12810175
Regulation of the balance of osteoblastic and osteoclastic activity is critical for the understanding of normal cell biology and forms the basis of metabolic bone diseases. Our study reports about...
10.
Ziegler S, Niessner A, Slany J, Muller M, Heinschink A, Billensteiner E, et al.
Acta Med Austriaca
. 2003 May;
30(2):55-8.
PMID: 12752090
In 19 marathon runners of both sexes, plasma concentrations of total creatine kinase (CK) activity, CKMB mass, myoglobin and troponin I were determined before and immediately after the race. Total...